

HOUSE BILL No. 1061

DIGEST OF INTRODUCED BILL

Citations Affected: IC 16-41-17.5.

Synopsis: Lyme disease information. Requires a health care provider or health care provider's designee who orders a laboratory test for the presence of Lyme disease to provide the patient or the patient's legal representative with certain written information concerning Lyme disease.

Effective: July 1, 2017.

Shackleford

January 4, 2017, read first time and referred to Committee on Public Health.



First Regular Session of the 120th General Assembly (2017)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in **this style type**, and deletions will appear in ~~this style type~~.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or ~~this style type~~ reconciles conflicts between statutes enacted by the 2016 Regular Session of the General Assembly.

HOUSE BILL No. 1061

A BILL FOR AN ACT to amend the Indiana Code concerning health.

Be it enacted by the General Assembly of the State of Indiana:

1 SECTION 1. IC 16-41-17.5 IS ADDED TO THE INDIANA CODE
2 AS A **NEW** CHAPTER TO READ AS FOLLOWS [EFFECTIVE
3 JULY 1, 2017]:

4 **Chapter 17.5. Prevention and Treatment Programs: Lyme**
5 **Disease Testing Information Disclosure**

6 **Sec. 1. As used in this chapter, "Lyme disease" means an**
7 **infection commonly:**

- 8 (1) **transmitted by a tick; and**
9 (2) **caused by the *Borrelia burgdorferi*, *Borrelia mayonii*,**
10 ***Borrelia afzelii*, or *Borrelia garinii* bacteria.**

11 **Sec. 2. A health care provider or health care provider's designee**
12 **who orders a laboratory test for the presence of Lyme disease shall**
13 **provide the patient or the patient's legal representative with the**
14 **following written information:**

15 **ACCORDING TO THE CENTERS FOR DISEASE**
16 **CONTROL AND PREVENTION, AS OF 2011, LYME**
17 **DISEASE IS THE SIXTH FASTEST GROWING DISEASE**



1 **IN THE UNITED STATES.**
2 **YOUR HEALTH CARE PROVIDER HAS ORDERED A**
3 **LABORATORY TEST FOR THE PRESENCE OF LYME**
4 **DISEASE FOR YOU. CURRENT LABORATORY TESTING**
5 **FOR LYME DISEASE CAN BE PROBLEMATIC, AND**
6 **STANDARD LABORATORY TESTS OFTEN RESULT IN**
7 **FALSE NEGATIVE AND FALSE POSITIVE RESULTS; IF**
8 **A TEST IS PERFORMED TOO EARLY, YOU MAY NOT**
9 **HAVE PRODUCED ENOUGH ANTIBODIES TO BE**
10 **CONSIDERED POSITIVE BECAUSE YOUR IMMUNE**
11 **RESPONSE REQUIRES TIME TO DEVELOP**
12 **ANTIBODIES.**
13 **IF YOU ARE TESTED FOR LYME DISEASE AND THE**
14 **RESULTS ARE NEGATIVE, THIS DOES NOT**
15 **NECESSARILY MEAN YOU DO NOT HAVE LYME**
16 **DISEASE. IF YOU CONTINUE TO EXPERIENCE**
17 **SYMPTOMS, YOU SHOULD CONTACT YOUR HEALTH**
18 **CARE PROVIDER AND INQUIRE ABOUT THE**
19 **APPROPRIATENESS OF RETESTING OR ADDITIONAL**
20 **TREATMENT.**

